Αποτελέσματα Αναζήτησης
The STAR trial has shown that raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of adverse events but a nonstatistically significant higher risk of noninvasive breast cancer.
The STAR trial has shown that raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of adverse events but a nonstatistically significant higher risk of noninvasive breast cancer.
5 Ιουν 2006 · STAR is a study that compared the drugs tamoxifen and raloxifene in reducing the risk of breast cancer in postmenopausal women at increased risk of the disease. The study found that both drugs were equally effective, but raloxifene had fewer side effects.
21 Ιουν 2006 · In this initial report of the STAR trial, raloxifene and tamoxifen were equivalent in efficacy for lowering the risk of invasive breast cancer. The cumulative incidence rates were 25.1 per 1000 women (raloxifene) vs 24.8 per 1000 (tamoxifen) ( P = .83).
9 Ιαν 2014 · The current study was designed to assess the severity and symptoms of obstructive sleep apnea before the implantation of the upper-airway stimulation device as compared with 12 months after ...
12 Οκτ 2006 · The National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial recently demonstrated that raloxifene, a selective estrogen-receptor modulator, was as...
the unblinding of the STAR trial in 2006, raloxifene has emerged as an option for reducing breast cancer risk for postmenopausal women at increased risk for the disease.
